Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.
Executives urge analysts to focus on the company's long-term potential.
The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union
Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.
Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.
Some recommendations to help marketers put their best foot forward on smartphone and tablet screens
What does it take to turn your booth into a world-class educational and entertainment experience? Here are five proven principles that consistently bring the magic to the show floor.
ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.
The FDA greenlighted the drug for three cancers.
A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
Missed MM&M's Skill Sets Live event on Engaging Patients? We're now giving you a second chance to get up to speed! Click here to access this insightful e-book with all the key take-aways.